YUHSpace

BROWSE

YUHSpace1. College of Medicine (의과대학)Dept. of Internal Medicine (내과학교실)

1. Journal Papers

This table browses all dspace content
Issue DateTitleJournal Title
2022Characteristics and clinical outcome of high-risk multiple myeloma patients in Korea (KMM 1805)INTERNATIONAL JOURNAL OF HEMATOLOGY
2022Carfilzomib Use Among Patients with Relapsed/Refractory Multiple Myeloma in the Asia Pacific Region: Characteristics and Outcomes By Regimen from a Prospective, Real-World StudyBLOOD
2022Phase III study of canakinumab (CAN) as adjuvant therapy in patients (pts) with completely resected non-small cell lung cancer (NSCLC)ANNALS OF ONCOLOGY
2022Busulfan and thiotepa as a conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-1801 study) FRONTIERS IN ONCOLOGY
2022Brigatinib (BRG) vs crizotinib (CRZ) in anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor-naive ALK+ non-small cell lung cancer (NSCLC): ALTA-1L final resultsANNALS OF ONCOLOGY
2022Biological insights into systemic lupus erythematosus through an immune cell-specific transcriptome-wide association study ANNALS OF THE RHEUMATIC DISEASES
2022Atezolizumab plus bevacizumab in Child-Pugh B advanced hepatocellular carcinoma patientsJOURNAL OF CLINICAL ONCOLOGY
2022Association between the Persistence of Obesity and the Risk of Gastric Cancer: A Nationwide Population-Based Study CANCER RESEARCH AND TREATMENT
2022Association Between Changes in Perivascular Adipose Tissue Density and Plaque ProgressionJACC-CARDIOVASCULAR IMAGING
2022Aspirin and Statin Therapy for Nonobstructive Coronary Artery Disease: Five-year Outcomes from the CONFIRM Registry RADIOLOGY-CARDIOTHORACIC IMAGING
2022Analysis of risk factors for recurrence of distal bile duct cancer without lymph node metastasis after curative resection: Is adjuvant therapy really required?ANNALS OF ONCOLOGY
2022Amivantamab in combination with lazertinib in patients with atypical epidermal growth factor receptor (EGFR) mutations excluding exon 20 insertion mutations: Initial results from CHRYSALIS-2ANNALS OF ONCOLOGY
2022Adjuvant trastuzumab plus pertuzumab (TP) versus trastuzumab (T) alone in patients achieving pathologic complete response after chemotherapy with 쎼ANNALS OF ONCOLOGY
2022Adherence to healthy lifestyle behaviors as a preventable risk factor for severe hypoglycemia in people with type 2 diabetes: A longitudinal nationwide cohort study JOURNAL OF DIABETES INVESTIGATION
2022A Single-Arm, Open-Label, Multicenter Study to Assess Molecular Response of P1101 Therapy in Patients with Polycythemia Vera and Elevated HematocritBLOOD
2022A scoring model to predict the clinical outcome of self-expandable metal stents in patients with colorectal obstruction due to extracolonic malignancyANNALS OF ONCOLOGY
2022LBA7 A randomized, double-blind, multinational phase III study to assess the efficacy and safety of lazertinib versus gefitinib in the first-line treatment of patients with EGFR mutation (EGFRm), advanced NSCLC (LASER301; NCT04248829)ANNALS OF ONCOLOGY
2022A Potent Small Molecule Inhibitor of FLT3, PHI-101 Overcomes Resistance in Acute Myeloid Leukemia: Efficacy and PK/PD Profile in Phase 1 First in Human StudyBLOOD
2022A phase I-II multicenter, open-label, dose-escalation study to evaluate the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of ABN401 in patients with advanced solid tumors and dose-expansion in patients with non-small cell lung cancer harboring c-MET dysregulationANNALS OF ONCOLOGY
2022A phase II, multicenter study of lazertinib as consolidation therapy in patients with locally advanced, unresectable, EGFR mutation-positive non-small cell lung cancer (stage III) who have not progressed following definitive, platinum-based, chemoradiation therapy (PLATINUM trial) THORACIC CANCER
1 60 6162636465666768697071 691

Recent Submissions

  • License
    sherpa_romeo
    sherpa_juliet

OAK

DSpace Software Copyright © 2002-2017 Duraspace Yonsei University Medical Library All right Reserves. / TEL:02-2228-2915 /
YUHSpace는 국립중앙도서관 OAK 보급사업으로 구축되었습니다.

Browse

Links